Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 245-629-3 | CAS number: 23386-52-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- The study was conducted to the highest possible scientific standards in a well renomated laboratory, however only limited materials and methods were provided according to the standards at the time of conduct.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- The study was conducted to the highest possible scientific standards in a well renomated laboratory, however only limited materials and methods were provided according to the standards at the time of conduct.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Objective of study:
- absorption
- excretion
- metabolism
- GLP compliance:
- no
- Radiolabelling:
- yes
- Remarks:
- carbon-14
- Species:
- dog
- Strain:
- not specified
- Sex:
- not specified
- Route of administration:
- other: orally and intravenously
- Vehicle:
- water
- Remarks:
- Doses / Concentrations:
1. Dog S14 (8.0 kg) received 8.0 mL of a 1% solution of docusate sodium in water intravenously. Dog R300 (9.7 kg) received orally 97 mg docusate sodium in a gelatin capsule.
2. Two male beagle dogs were dosed with 4 mg/kg radiolabeled docusate sodium. Dog R872 (13.3 kg) was given 5.3 mL of a 10 mg/mL aqueous solution intravenously. Dog R613 (8.4 kg) received 33.6 mg in a gelatin capsule. - Control animals:
- no
- Details on dosing and sampling:
- 1. Non-radioactive compound: Urine was collected at 0-24h and 24-48 hours. Whole blood (5 mL) was collected from dog S14 at 10, 20 and 30 minutes and from both animals at 1, 2, 4 and 8 hours after dose.
2. Radioactive compound: Plasma was obtained from dog R872 at 5, 10, 15, 20, 30 and 45 minutes after injection and from dog No. R613 at 15 and 35 minutes after dosage. Plasma was taken from both animals at 1, 2, 3, 4, 7 and 48 hours after dosage. Total urine was collected at 0-7, 7-24 and 24-48 hours. Feces were collected at 0-24 and 24-48 hours. - Type:
- absorption
- Results:
- min. 5%
- Type:
- excretion
- Results:
- in the urine (25%) and feces (70%)
- Details on absorption:
- Table 1 shows the results of the analyis of the blood from the 2 dogs receiving unlabeled test compound. Analysis of the urine from the dogs produced values equivalent to 4% of the dose in the 0-24 hour sample of each animal.
As shown in Table 2, the similarity in distribution of activity between urine and feces between intravenous and oral dosage is suggestive that the orally adminstered compound is completely absorbed. There is little difference between the two routes.
Table 3 shows the concentration of radioactivity in the plasma of the two dogs dosed with labeled DSS. A peak concentration of radioactivity occurred in the orally dosed animal at 1 hour. After an initial rapid removal of the compound from the blood stream the half-life of the radioactivity in dog R872 became 19 hours and that for dog R613, 14 hours between 7 and 24 hours afer dosage. - Metabolites identified:
- no
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
The compound was well excreted after oral administration (75% was found in the faeces, whereas 25% was found in the urine). - Executive summary:
The absorption, excretion and metabolism of dioctyl sodium succinate (DSS) have been investigated in dogs by means of unlabeled and radiolabeled (carbon-14) compound. A peak concentration of radioactivity occurred in the orally dosed animal at 1 hour. Analysis of the urine from the dogs produced values equivalent to 4 -7% of the dose in the 0-24 hour samples. A comparison of an oral and intravenous dose of 4 mg/kg carbon-14 DSS in the dog yielded remarkably similar excretion patterns and metabolic profiles. In each case 71% of the administered radioactivity was excreted in the faeces. Countercurrent distribution curves on the urine of these animals were almost identical.
Table 1. Concentration of 2-ethylhexanol-forming compounds in the blood of 2 dogs after dosage with 10 mg/kg DSS
Concentrations expressed in µg/mL DSS equivalents
Time after dosage |
Dog S14 (I.V.) |
Dog R300 (oral) |
|
(min.) |
(hour) |
||
10 |
|
42 |
- |
20 |
|
28 |
- |
30 |
|
27 |
- |
|
1 |
10 |
5 |
|
2 |
3 |
3 |
|
4 |
1 |
1 |
|
8 |
0 |
0 |
-: not determined
Table 2. Excretion of radioactivity by 2 dogs which received 4 mg/kg carbon-14 labeled DSS
|
% of Dose |
|||||
Hours after dose |
Dog R872 (intravenous) |
Dog R613 (oral) |
||||
Urine |
Feces |
Total |
Urine |
Feces |
Total |
|
0-7 |
14.6 |
- |
14.6 |
12.3 |
- |
12.3 |
7-24 |
4.6 |
0.4 |
5.0 |
7.6 |
0 |
7.6 |
24-48 |
2.2 |
66.9 |
69.1 |
4.2 |
65.6 |
69.8 |
48-72 |
1.8 |
3.6 |
5.4 |
1.1 |
5.2 |
6.3 |
72-96 |
0.8 |
0.1 |
0.9 |
0.3 |
0.3 |
0.6 |
Cummulative totals |
24.0 |
71.0 |
95.0 |
25.5 |
71.1 |
96.6 |
-: not determined
Table 3. Concentration of radioactivity in the plasma of 2 dogs which received 4 mg/kg carbon-14 labeled DSS concentrations expressed in µg/mL DSS
Time after dosage |
Dog 872 (I.V.) |
Dog R6113 (oral) |
5 min. |
45.1 |
- |
10 min. |
28.8 |
- |
15 min. |
23.4 |
0.01 |
20 min. |
18.8 |
- |
30 min. |
12.3 |
- |
35 min. |
- |
1.7 |
45 min. |
7.4 |
- |
1 hour |
5.9 |
7.4 |
2 hour |
2.8 |
4.2 |
3 hour |
1.9 |
1.7 |
4 hour |
1.5 |
1.2 |
7 hour |
1.0 |
0.68 |
24 hour |
0.52 |
0.26 |
48 hour |
0.26 |
0.09 |
72 hour |
0.14 |
0.03 |
96 hour |
0.11 |
0.02 |
- no sample obtained
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- The study was conducted to the highest possible scientific standards in a well renomated laboratory, however only limited materials and methods were provided according to the standards at the time of conduct.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Objective of study:
- absorption
- excretion
- GLP compliance:
- no
- Radiolabelling:
- yes
- Remarks:
- carbon-14
- Species:
- rabbit
- Strain:
- not specified
- Sex:
- female
- Route of administration:
- other: orally and intravenously
- Vehicle:
- water
- Remarks:
- Doses / Concentrations:
Rabbit No. 1 (4.0 kg) was given 1.6 mL of a 10 mg/mL solution in water intravenously.
Rabbit No. 2 (3.6 kg) was given 14.4 mg in a gelatin capsule. - Control animals:
- no
- Details on dosing and sampling:
- Urine and faeces were collected at 0-24, 24-48, 48-72 and 72-96 hours.
- Type:
- absorption
- Results:
- 90%
- Type:
- excretion
- Results:
- in the urine (93-99%) and feces (4-5%)
- Details on absorption:
- Table 1 shows the results of the analyis of the urine and faeces.
- Metabolites identified:
- no
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
The compound was well absorbed, metabolised and excreted after oral administration (70% were oberved in the 24 hours urine; 90% in total). - Executive summary:
The absorption and excretion of docusate sodium (dioctyl sodium succinate, DSS) have been investigated in rabbits by means of radiolabeled (carbon-14) compound . The results demonstrate good absorption of the radiolabel by the rabbit following oral dosage, over 90% of administered radioactivity being excreted in the urine. It is concluded that DSS is absorbed intact by the rabbit rather than being hydrolysed in the gastrointestinal tract.
Table 1. Excretion of radioactivity by 2 rabbits which received 4 mg/kg carbon-14 labeld DSS
|
% of Dose |
|||||
Hours after dose |
Rabbit No. 1 (intravenous) |
Rabbit No. 2 (oral) |
||||
Urine |
Feces |
Total |
Urine |
Feces |
Total |
|
0-24 |
87.1 |
2.3 |
89.4 |
69.7 |
3.1 |
72.8 |
24-48 |
8.8 |
0.5 |
9.3 |
17.4 |
1.0 |
18.4 |
48-72 |
2.1 |
0.4 |
2.5 |
5.3 |
0.7 |
6.0 |
72-96 |
0.9 |
0.4 |
1.3 |
1.1 |
0.4 |
1.5 |
Cummulative totals |
98.9 |
3.6 |
102.5 |
93.5 |
5.2 |
98.7 |
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- The study was conducted to the highest possible scientific standards in a well renomated laboratory, however only limited materials and methods were provided according to the standards at the time of conduct.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Objective of study:
- absorption
- excretion
- metabolism
- GLP compliance:
- no
- Radiolabelling:
- no
- Species:
- human
- Strain:
- not specified
- Sex:
- male
- Route of administration:
- oral: capsule
- Remarks:
- Doses / Concentrations:
Two male volunteers were each given two 100 mg capsules. - Control animals:
- no
- Details on dosing and sampling:
- Total urine was collected from the subjects at 0-7.5, 7.5-24, 24-48 hours after dosage. Blood samples (10 mL) were collected at 0, 1.5, 1, 2, 4 and 8 hours after dosage and centrifuged to obtain serum. The sera and urine were frozen immediately and maintained in the frozen stte until analyzed.
- Type:
- absorption
- Results:
- min. 5%
- Type:
- excretion
- Results:
- in the urine (25%) and feces (70%)
- Details on absorption:
- Table 1 shows the results of the serum concentration of the 2 human volunteers dosed with 200 mg.
- Metabolites identified:
- no
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
Peak concentrations of docusate sodium in serum occurred at 2 hours after dosage. The excretion of 2-ethylhexanol derivatives in the urine of man accounted for only a very small amount of the administered dose of docusate sodium. - Executive summary:
In man, peak concentrations of docusate sodium in serum occurred at 2 hours after dosage with 200 mg. These values, in two men, were 7,9 and 5,5 µg/mL, similar in magnitude to the plasma concentration seen at 1 hour in the orally dosed dog (7,4 µg/mL) which received 4 mg/kg. The analysis of human serum was done by gas chromatography and that of dog plasma by the radiometric method. The excretion of 2-ethylhexanol derivatives in the urine of man accounted for only a very small amount of the administered dose of docusate sodium, a finding similar to that seen in the urine of the dog. An attempt to compare the urine of man and the dog by analysis of 2-ethylhexanol forming compounds in countercurrent distribution fractions did not yield fruitful results.
Table 1. Concentrations of 2-ethoxylhexanol forming compounds in the serum of 2 subjects after a single 200 mg dose
of DSS (concentrations expressed in µg/mL DSS)
Hours after dosage |
Subject 1 |
Subject 2 |
0 |
0 |
0 |
0.5 |
0 |
2.7 |
1 |
4.7 |
4.0 |
2 |
7.9 |
5.5 |
4 |
3.4 |
1.0 |
8 |
2.0 |
0.3 |
Table 2. Concentrations of 2-ethoxylhexanol forming compounds in the urine of 2 subjects after a single 200 mg dose of
DSS (concentrations expressed in percent of dose)
Hours after dosage |
Subject 1 |
Subject 2 |
0 |
0 |
0 |
0-7.5 |
3.8 |
0.3 |
7.5-24 |
0.9 |
2.0 |
24-48 |
0.8 |
0.2 |
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 973
- Report date:
- 1973
Materials and methods
- Objective of study:
- absorption
- excretion
- metabolism
- GLP compliance:
- no
Test material
- Reference substance name:
- Docusate sodium
- EC Number:
- 209-406-4
- EC Name:
- Docusate sodium
- Cas Number:
- 577-11-7
- Molecular formula:
- C20H38O7S.Na
- IUPAC Name:
- sodium 1,4-bis[(2-ethylhexyl)oxy]-1,4-dioxobutane-2-sulfonate
- Reference substance name:
- Butanedioic acid, sulfo-, 1,4-bis (2-ethylhexyl) ester, sodium salt
- IUPAC Name:
- Butanedioic acid, sulfo-, 1,4-bis (2-ethylhexyl) ester, sodium salt
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): dioctyl sodium succinate (DSS)
- Substance type: sulfosuccinate compound
- Physical state: liquid
Constituent 1
Constituent 2
- Radiolabelling:
- no
- Remarks:
- 5 rats unlabeled; one male rat carbon-14 labeled
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- other: oral gavage and intravenously
- Vehicle:
- water
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1. Five rats were dosed with unlabeled docusate sodium. Rat No. 1 received 1 mL and rat No. 3 received 2 mL of a 5 mg/mL solution in water by oral gavage. Rats Nos. 4 and 5 received 1 mL of a 1% solution in water by intravenous administration. In addition, one animal (rat No. 2) was given 1.05 mL of a solution of 5.5 mg/mL 2-ethyl-hexanol in 40% ethanol by oral gavage.
2. One male rat (250 g) was given 10 mg/kg 14C labeled docusate sodium by gavage (2.5 mL of a 1 mg/mL solution).
- Control animals:
- no
- Details on dosing and sampling:
- 1. Total urine and feces were collected from all of the animals at 24 and 48 hours after dosage. Urine and feces from rat No. 1 were also collected at 72 hours and 96 hours.
2. Urine and feces were collected from the rat given 14C labeled DSS at 0-24h and 24-48 hours.
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- at least 65%
- Type:
- metabolism
- Results:
- extensive (e.g. 2-ethylhexanol)
- Type:
- excretion
- Results:
- in the urine (within 24h) and feces
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Table 1 shows the results of the analysis of the urine from these animals using the 2-ethylhexanol distillation procedure. The 24-48 hour urine samples from any of the animals did not yield measurable quantities of 2-ethylhexanol. Since the percent of dose excreted in the urine after intravenous dosage was comparable to the excretion after oral dosage, it is concluded that the orally administered compound is well absorbed by the rat. Since 2-ethylhexanol derivatives recovered in the urine after administration of the alcohol are appreciably lower than those recovered after DSS administration, it is concluded that the mechanism of absorption of DSS does not include prior hydrolysis of the ester groups in the gastrointestinal tract. This is further substantiated by the finding that the 2-ethylhexanol forming compound in urine after administration with DSS is largely not the free alcohol or its glucuronide conjugate.
- Details on excretion:
- The male animal given radioactive compound showed that the urine excreted during the first 24 hours accounted for 64.1% of the radioactivity; the feces for 37.4%. The animal was further found to eliminate 1.0% of the dose in the 24-48h urine and 0.9% of the dose in the 24-48h feces.
Metabolite characterisation studies
- Metabolites identified:
- yes
Any other information on results incl. tables
Table 1. 24 hour excretion of 2-ethylhexanol-forming compounds by the rat after oral dosage with DSS and 2-ethylhexanol
Rat No. |
Compound |
Dose (mg) |
Route |
% of dose excreted |
|
Urine |
Faeces |
||||
1 |
DSS |
5 |
oral |
18.6 |
0.9 |
3 |
DSS |
10 |
oral |
15.5 |
8.7 |
4 |
DSS |
10 |
I.V. |
12.3 |
- |
5 |
DSS |
10 |
I.V. |
15.5 |
- |
2 |
2-ethyl-hexanol |
5.8 |
oral |
3.1 |
3.9 |
-: not determined
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
The compound was well absorbed, metabolised and excreted after oral administration (two thirds were oberved in the 24 hours urine; one third was found in the feces). - Executive summary:
The absorption, excretion and metabolism of dioctyl sodium succinate (DSS) have been investigated. Unlabeled DSS and radiolabeled compound (carbon-14) were used. Using a gas chromatographic procedure, a similarity in percent excretion of dose into urine was observed in rats dosed orally and intravenously, indicating a high degree of absorption of the oral dose. Confirmation of extensive absorption of DSS was obtained through oral dosage of 10 mg/kg carbon-14 labeled compound. Two thirds of the administered radioactivity was found in the urine at 24 hours after dosage. All of the activity was in the form of metabolites (2-ethylhexanol forming compounds).
.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.